← Core Laboratories Inc. /DE/
| Annual Trend | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Total Revenue | $470.3m |
$489.7m
+4.14%
|
$509.8m
+4.10%
|
$523.8m
+2.76%
|
$526.5m
+0.51%
|
|
| Cost of Revenue | $380.8m |
$410.1m
+7.69%
|
$414.9m
+1.17%
|
$420.5m
+1.36%
|
$417.6m
-0.70%
|
|
| Cost of services and product sales exclusive of depreciation expense shown below | $367.9m |
$393.7m
+7.00%
|
$400.0m
+1.60%
|
$420.5m
+5.14%
|
$417.6m
-0.70%
|
|
| Gross Profit (Calculated) (derived) | $89.4m |
$79.6m
-10.95%
|
$94.9m
+19.16%
|
$103.3m
+8.88%
|
$108.9m
+5.43%
|
|
| General and Administrative Expense | $44.2m | $38.1m | $40.3m | $39.8m | $45.4m | |
| Amortization of Intangible Assets | $762k | $685k | $490k | $504k | $359k | |
| Operating expenses: | ||||||
| Operating Income (Loss) | $45.3m |
$41.5m
-8.26%
|
$54.6m
+31.59%
|
$58.6m
+7.17%
|
$56.5m
-3.57%
|
|
| Interest Expense | $9.2m | $11.6m | $13.4m | $12.4m | $10.6m | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | $229k | $176k | ($1.2m) | ($745k) | |
| Other Nonoperating Income (Expense) | $45.3m | ($722k) | ($850k) | $10.0m | $7.6m | |
| Income (Loss) from Equity Method Investments | $36.1m | $30.0m | $41.2m | $46.2m | $45.9m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | ($4.1m) | $3.9m | ($11.0m) | ($3.2m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $36.1m | $30.0m | $41.2m | $46.2m | $45.9m | |
| Current Income Tax Expense (Benefit) | — | $11.0m | $15.2m | $13.4m | $14.1m | |
| Income Tax Expense (Benefit) | $15.9m | $10.3m | ($4.2m) | $14.0m | $15.5m | |
| Net Income (Loss) Attributable to Parent | $19.7m |
$19.5m
-1.39%
|
$36.7m
+88.53%
|
$31.4m
-14.38%
|
$29.7m
-5.51%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | $492k | $205k | $350k | $753k | $722k | |
| Earnings Per Share, Basic | $0.43 | $0.42 | $0.79 | $0.67 | $0.64 | |
| Earnings Per Share, Diluted | $0.42 | $0.42 | $0.77 | $0.66 | $0.63 | |
| Income (Loss) from Continuing Operations, Per Basic Share | — | $0 | $1 | $1 | $1 | |
| Income (Loss) from Continuing Operations, Per Diluted Share | — | $0 | $1 | $1 | $1 | |
| Weighted Average Number of Shares Outstanding, Basic | 46.0m | 46.3m | 46.7m | 46.9m | 46.4m | |
| Weighted Average Number of Shares Outstanding, Diluted | 46.7m | 46.8m | 47.5m | 47.7m | 47.0m | |
| Additional Financial Items | ||||||
| Depreciation | $17.8m | $16.5m | $15.3m | $14.4m | $14.3m | |
| Other (income) expense, net | ($5.6m) | ($722k) | ($850k) | ($10.0m) | ($7.6m) |